Status: Not yet recruiting
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2 positive advanced solid tumors? Participants will receive Zanidatamab intravenously on Day 1 of each 2-week treatment cycle. The dosage is 20 mg/kg per cycle.
Participants needed: 10
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Haihua YuanUpdated: Jun 8, 2026
Eligibility criteria
Male or female subjects aged ≥ 18 years old. [+7]
Documented spinal cord compression, leptomeningeal disease or clinically active... [+5]